Business Context and Reporting Period
Company: Spruce Biosciences, Inc. (SPRB)
Filing Type: Form 10-K (Annual Report)
Period Covered: Fiscal year ended December 31, 2024
Business Overview: Spruce is a late-stage biopharmaceutical company developing therapies for neurological disorders. Its primary assets include TA-ERT (tralesinidase alfa) for Mucopolysaccharidosis Type IIIB (MPS IIIB), tildacerfont for Major Depressive Disorder (MDD) and Congenital Adrenal Hyperplasia (CAH), SPR202 for CAH, and SPR204 for Post-Bariatric Hypoglycemia. The company has no approved products and has not generated product revenue.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Collaboration Revenue | $4.9 million | $10.1 million |
| Total Operating Expenses | $61.1 million | $62.1 million |
| Net Loss | $(53.0) million | $(47.9) million |
| Cash and Cash Equivalents (Year End) | $38.8 million | $96.3 million |
| Accumulated Deficit | $(250.3) million | $(197.2) million |
| Debt Outstanding (Term Loan) | $1.8 million | $3.4 million |
Note: The company reported a net loss per share of $(1.29) for 2024 compared to $(1.24) for 2023.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by $5.2 million (51%) to $4.9 million. This was due to the recognition of the remaining balance from the Kaken Pharmaceutical upfront payment, which was fully recognized by year-end 2024.
- Asset Acquisition: In October 2024, the company acquired the TA-ERT program and related assets from Allievex Corporation. This resulted in a one-time R&D expense of approximately $15.1 million (including assumed liabilities) and increased manufacturing costs by $3.9 million year-over-year.
- Cash Burn: Cash used in operating activities increased to $56.0 million in 2024 from $33.3 million in 2023. Total cash reserves dropped by approximately $57.6 million during the year.
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern, stating that current cash ($38.8 million) is insufficient to fund operations for at least 12 months following the report date.
Guidance, Outlook, and Risks
- TA-ERT (MPS IIIB): The company intends to submit a Biologics License Application (BLA) for accelerated approval in the first half of 2026. A confirmatory Phase 3 trial must be initiated prior to approval.
- Tildacerfont (MDD): A Phase 2 proof-of-concept trial (TAMARIND) with partner HMNC is underway, with topline results expected in the first half of 2026.
- Recent Partnerships:
- HBM Alpha Therapeutics (Jan 2025): Acquired exclusive license for SPR202 (CAH) for $5.0 million upfront plus equity warrant.
- Twist Bioscience (Dec 2024): Acquired license for SPR204 (Post-Bariatric Hypoglycemia).
- Financing Needs: The company explicitly states it requires substantial additional financing to continue clinical development and operations. Failure to secure funding could force delays or cessation of programs.
- Listing Status: The company transferred its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market in October 2024 due to stock price falling below $1.00. It has until April 21, 2025, to regain compliance with the minimum bid price requirement.
- Legal Proceedings: Neurocrine Biosciences filed suit in January 2025 seeking to invalidate one of Spruce's patents and initiated administrative proceedings against others.
Investor Verification Checklist
- Liquidity Runway: Verify the company's ability to raise capital given the "substantial doubt" regarding going concern status and the $38.8 million cash balance.
- TA-ERT Regulatory Path: Confirm the timeline and design of the required confirmatory Phase 3 trial for TA-ERT, as accelerated approval is contingent on its initiation.
- Patent Litigation: Monitor the outcome of the patent invalidation suit filed by Neurocrine Biosciences in January 2025.
- Nasdaq Compliance: Track the stock price to ensure it meets the $1.00 minimum bid price requirement by April 21, 2025, to avoid delisting.
- Debt Covenants: Review the terms of the Silicon Valley Bank term loan (maturing Jan 2026) to ensure compliance with covenants and repayment schedules.